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ABSTRACT

Glucagon-like peptide-1 (GLP-1) and exendin-4 (Ex-4) are small peptides
with potent insulin secretory effect which makes them attractive drug candidates for
the treatment of Type 2 diabetes mellitus (T2DM). However, the synthesis of these
small peptides is difficult due to recombinant protein degradation and instability.
Human serum transferrin (hTf) is an iron-transport protein that has great potential as
an efficient carrier system for protein-based drugs. The use of hTf as a fusion partner
will provide a new strategy to enhance the therapeutic potential of GLP-1 and Ex-4.
This project investigates the development of transgenic tobacco plants as bioreactors
for generating recombinant fusion proteins, GLP-1 - hTf and Ex-4 - hTf. Here,
transgenic tobacco plants have successfully accumulated recombinant fusion proteins.
Plant-derived proteins showed stability in simulated gastrointestinal environment and
confirmed their ability to stimulate insulin secretion from a pancreatic (l-cell line in
vitro. Lastly, hTf-fused proteins were shown to internalize into human intestinal
epithelial cells in vitro. Collectively, the results suggest that transgenic plants are an
effective expression and delivery system of recombinant anti-diabetic proteins.

Key Words:

transgenic tobacco, glucagon-like peptide-1, exendin-4, oral

administration, recombinant therapeutic proteins, fusion proteins, Agrobacteriummediated transformation, Type 2 diabetes mellitus
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Chapter 1
General Introduction

1.1

Expression

systems

for

production

of

recombinant

proteins

of

pharmaceutical interest
To date, a number of biological expression systems such as bacteria, yeast,
and mammalian cells have been widely available for the production of recombinant
pharmaceutical proteins.

Recombinant proteins are generally synthesized by large-

scale cultivation of genetically engineered “host” cells, which harbour artificially
transfected genes encoding proteins of interest (Manuel et al., 2007). For protein
therapeutics to be effective, they must be synthesized in a biologically active form,
which requires proper folding and appropriate post-translational modifications
(Sethuraman and Stadheim, 2006). Conventional systems, including bacteria, yeast,
and mammalian cell cultures, have advantages and disadvantages for production of
recombinant proteins.
Bacteria such as Escherichia coli have been the most common host for
therapeutic protein production. Bacterial systems provide relatively high expression
level of recombinant protein as well as the potential for large-scale production
(Skerra, 1993). However, all bacteria are prokaryotic organisms and cannot perform
post-translational modifications that regulate protein folding and biological activity
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of eukaryotic proteins, which makes bacteria not suitable for expressing complex
proteins such as antibodies and therapeutics (Georgiou and Valax, 1996; Baibas,
2001).
Unlike the bacterial systems, yeast, a single-cell eukaryotic organism,
harbours the machinery able to perform some of the post-translational modifications
and provides easy manipulation and cultivation. However, the ability of yeast to
perform post-translational modification of heterologous proteins is limited (Hamilton
et al., 2003; Wildt and Gemgross, 2005). Moreover, yeast-derived proteins are often
hyper-glycosylated due to the repeated addition of mannose at N-linked sites which
can hinder biological activity of proteins (MacKays, 1987; Kniskem et ah, 1994).
Mammalian cell cultures offer a better choice as they can produce
recombinant proteins with accurate post-translational modifications. Despite this,
mammalian cell cultures are limited by their production cost due to expensive media
and subsequent purification methods, thereby impeding the economic and
commercial value of recombinant proteins for therapeutic use. The scale-up is low
and often not feasible, and protein yields are lower than in any other systems. In
addition, there is a possibility of viral contamination, and if the host is human cellderived or the virus is capable of cross-species infection, serious complications can
arise (Kojima et ah, 1996; O’Callaghan and James, 2008)
Recently, there has been a significant increase in the demand of protein-based
therapeutics such as antibodies, growth factors and insulin.

Novel production

strategies must be implemented in order to meet the ever increasing demand for
recombinant therapeutic market, while allowing cost-effective large-scale production.

3

1.1.1 Plant expression system for recombinant proteins
Major advances have been made over the last two decades to improve the
expression and accumulation of recombinant proteins in plant systems.

The

recombinant production of pharmaceuticals, functional proteins, industrial enzymes
and functional secondary metabolites in plants is referred to as “plant molecular
farming” (PMF) (Ma et al., 2005). The first reported pharmaceutical protein made in
plants was tobacco callus expressing human growth hormone (Barta et al., 1986).
To date, several proteins of medical interest have been expressed successfully in
plants, including a variety of antibodies, vaccine antigens, protein allergens, enzymes,
cytokines and hormones (Hiatt et al., 1989; Mason et al., 1992; Ma et al., 1995, 2003,
2005; Kirk and Webb, 2005; Floss et al., 2007). As our understanding of the factors
that impact transgene expression in plants improves, we will see enhancement in
recombinant protein production and greater overall exploitation of plant-based
expression systems.

1.1.2 Advantages of plant expression systems
Plants have advantages compared with traditional systems for molecular
farming of pharmaceutical proteins. These include: 1) Low cost. The production of
recombinant proteins in plants does not require the costly equipment or media that
bacteria or mammalian cell cultures demand. Essentially, plants can be grown in the
field requiring only water and sunlight.

Furthermore, protein isolation and

purification may not even be necessary if the recombinant proteins are produced in
edible plant tissues and intended to be used for oral consumption (Barta et al., 1986;
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de Smit et al., 1995; Mason et al., 1998; Tacket et al., 1998). 2) Easy scale-up.
Transgenic plants have a high production capacity with nearly unlimited scalability.
Industrial level production can be achieved by increasing acreage.

3) Ability to

perform post-translational modifications required to assemble functional recombinant
proteins, in a similar fashion to a mammalian cell (Gomord and Faye, 2004). 4)
Safer products. Recombinant proteins produced in transgenic plants are less likely to
be contaminated with human pathogenic microorganisms, such as viruses and prions,
than those derived from mammalian cell, since plants do not act as hosts for human
infectious agents (Giddings et al., 2000).

1.1.3 Strategies for plant transformation
There are two basic methods for expressing recombinant foreign proteins in
plants.

One involves the generation of transgenic plants by stable genomic

integration of a transgene.

The other involves the expression of transgenes in

transiently transformed plants or tissues.
disadvantages (Fisher et al., 2000).

Each approach has its advantages and

Both strategies involve a soil-borne plant

pathogen known as Agrobacterium tumefaciens, which has been widely used for the
transformation of plants such as tobacco (Horsch et al., 1985). The molecular
mechanisms of Agrobacterium-mediated transformation are now well understood
(McCullen et al., 2006; Wenck et al., 1997).
Compared to stable plant transformation, transient gene expression is rapid
and relatively simple to handle, and the experiment is usually completed within a
week. Furthermore, the absence of chromosomal position effects allows for better
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reproducibility and reliable levels of gene expression in transient assays (Janssen et
al., 1990).

Transient expression allows higher protein accumulation when

recombinant gene is co-expressed with p i9. This viral p i 9 protein suppresses the
post-transcriptional gene silencing in plant systems (Voinnet et al., 2003). Transient
gene expression, however, is limited in scale and is neither permanent nor heritable.
In contrast, stably transformed plants allow for the permanent and heritable
expression of a particular gene, although generating stably transformed plants
requires a longer scale-up time. With these advances in plant expression systems, the
development of protein drugs for human disease, such as diabetes, is gaining an
increased interest.

1.2

Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is a progressive and complex disorder that

is characterized by insulin deficiency and insulin resistance (Bethel and Feinglos,
2005).

Most

conventional

anti-diabetic

agents,

including

sulfonylureas,

thiazolidinediones, and insulin, improve glycaemic control, but these are associated
with pancreatic P-cell reduction, cardiovascular problems and undesired weight gain
(Holst, 1997). New treatment options are needed for patients to gain glycaemic
control and to reduce the risk of serious health complications.

1.3

Glucagon-like peptide-1 and Exendin-4 for T2DM treatment
Glucagon-like peptide-1 (GLP-1) is a major incretin hormone, a potent blood

glucose-lowering hormone, secreted by intestinal L cells in the small intestine and
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colon (Holst, 2007). GLP-1 is a small peptide (31 amino acids) and is released in
response to food ingestions, particularly to intake of carbohydrates and fats (Holst,
2007).

Secreted GLP-1 promotes insulin production from pancreatic P-cells in a

glucose-dependent manner, which reduces the risk of hypoglycaemia (Holst, 2007).
Besides its insulinotropic activities, GLP-1 has been shown to inhibit glucosedependent glucagon secretion, delay gastric emptying and decrease food intake,
resulting in weight loss (Turton et al., 1996; Flint et al., 1998; Drucker, 2003).
Furthermore, GLP-1 improves P-cell function by promoting p-cell proliferation and
inhibiting apoptosis (Gromada et al., 2004; McIntosh et al., 2005). However, GLP-1
released into the blood circulation is rapidly cleaved by dipeptidyl-peptidase-IV
(DDP-IV) into smaller peptides causing its inactivation (Orskov et al., 1993). The
rapid degradation of GLP-1 shortens its biological half-life to less than 2 minutes
(Schepp et al., 1994), prompting the search for analogs with longer durations of
action.
Exendin-4 (Ex-4) is a 39 amino acid peptide isolated from the salivary glands
of Gila monster (Heloderma suspectum) (Eng et al., 1992).

It is a functional

homolog of GLP-1 (53% amino acid identity) and it is reported to show agonistic
activity to GLP-1 receptors (GLP-1R) (Fehmann et al., 1994; Deacon et al., 1995;
Kieffer et al., 1995; Nielsen et al., 2004). It has all the same therapeutic benefits as
GLP-1 and more importantly, it is resistant to DPP-IV cleavage that allows for a
longer biological half-life than GLP-1 (Deacon et al., 1995; Kieffer et al., 1995).
Exendin-4 showed a glucose-lowering action that endured for several hours in a
diabetic mouse model (Martin et al., 2009). In addition, Exenatide (a synthetic form
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of exendin-4) improved glycemic control, reduced cardiovascular risk factors, and
allowed weight loss in T2DM patients in a 3-year clinical study (Nielsen et al., 2004).
The therapeutic advantages of exendin-4 and GLP-1 offer a great potential for the
treatment of T2DM patients.

1.4

Human Transferrin as a molecular carrier
Much research has focused on identifying and characterizing molecular

carriers that have the potential to transport therapeutic agents to specific target cells.
Human transferrin (hTf) is a 80kDa monomeric glycoprotein consisting of
approximately 679 amino acids (Gomme and McCan, 2005). The molecule contains
functionally related N-terminal and C-terminal domains that serve as binding sites for
iron (Fe3+) (Qian et al., 2002). Human Tf is synthesized predominantly in the liver
by hepatocytes. It is readily found in various body fluids including plasma, bile,
amniotic, cerebrospinal and lymph fluids (Li and Qian, 2002). As a major iron
transport protein, hTf plays a vital role in human physiology. It is involved in iron
uptake and regulation, cellular growth and differentiation, and is also involved in
cytokine production and antimicrobial activity (Gomme and McCann, 2005; Park et
al., 2009). It regulates iron concentration in many metabolic processes and prevents
free iron from reaching toxic levels in the body which can lead to free radical
formation and lipid peroxidation (Li and Qian, 2002). Studies have reported hT f s
efficiency in iron transportation to different cell types possessing surface transferrin
receptors (TfR) (Li and Qian, 2002). Human Tf receptors are found on the surfaces
of erythrocytes, thyroid cells, hepatocytes, intestinal cells and brain cells (Padron et
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al., 2006). The cellular uptake of iron is carried out by ligand-receptor-mediated
endocytosis (Figure 1; Li and Qian, 2002). The process is initiated by high-affinity
binding of the hTf-Fe3+ complex to TfR (Morgan and Appleton, 1969). The Fe3+hTf-TfR complex enters the cell through endosome formation (Qian et ah, 2002).
The pH inside the matured endosome drops to about 5.5, at which point the irons are
released from hTf (Klausner et ah, 1983). The released irons are sent to the cytosol
via a ferrous iron transporter to be used in cellular processes (Qian et ah, 2002).
This mechanism of iron delivery has attracted increased interest from the field of
therapeutic drug delivery because it shows potential for engineering hTf to introduce
drugs or therapeutic proteins to specific target cells.
Besides its efficient transport mechanism, hTf presents many advantages as a
molecular carrier. Aside from iron, hTf can also bind to other metal ions such as
bismuth (Bi) and gallium (Ga) which are used in therapeutic and diagnostic
procedures, respectively (Li and Qian, 2002).

Furthermore, because hTf is a

naturally-occurring protein in humans, it does not induce immunogenic responses
and is virtually nontoxic (Jiang et ah, 2007). All these features make hTf a very
suitable carrier and have led to the development of hTf conjugates as a drug delivery
system in anticancer therapies (Kratz et ah, 1998; Jiang et ah, 2007).
With the aim of producing an efficient drug delivery system, hTf conjugates
have been created by attaching chemical linkers (Qian et ah, 2002). For example,
doxorubicin, an antineoplasmic agent, was conjugated to hTf by forming a stable
amide linkage (Kratz et ah, 1998). Likewise, tumour necrosis factor alpha (TNF-a),
an antitumor cytokine, was linked to hTf by a polyethylene glycol (PEG) linker
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Figure 1.
Receptor-mediated endocytosis of hTf. The cellular uptake of iron is carried out by
hTf-TfR -mediated endocytosis. Iron-bound hsTf binds to TfR on the cell surface.
The resulting complex enters the cell via endosome formation. Acidification caused
by proton pump activity triggers iron release from hTf. Released iron enters the
cytoplasm through a ferrous iron transporter (DMT1). Free hTf (Apo-hTf) are then
released back to extracellular space to repeat the cycle (Li and Qian, 2002).

10
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method, where one side of the linker molecule (maleimide-PEG) is attached to TNFa via amide bond and the other side is joined to hTf by forming a thioether bridge
(Jiang et al., 2007). Results of these hTf conjugates show increased potential for
specific targeting and inhibition of malignant cancer cells without causing any
toxicity (Kratz et al., 1998; Jiang et al., 2007).

The targeting is caused by an

increased cellular uptake of conjugated drugs in response to greater-than-normal TfR
expression on malignant cells, which is required for rapid cell proliferation (Kratz et
al., 1998; Jiang et al., 2007). Furthermore, hTf has attracted a great deal of attention
as a transport chaperone for fused therapeutics, intended for enhanced transport
across blood-brain barrier (Friden and Walus, 1993; Osborn et al., 2008) or to
enhance the therapeutic bioavailability upon oral delivery of protein and peptide
drugs (Bai et al., 2005; Widera et al., 2004).

Human Tf seems to be an ideal

candidate for further development of delivering various therapeutic agents including
anti-diabetic agents.

1.5

Progresses in the production of GLP-1, Ex-4 and hTf
For generation of small peptides such as GLP-1, the most commonly used

method is chemical synthesis which is often expensive and results in a low yield of
active peptide product (Kimmerlin and Seebach, 2005).

Recombinant DNA

technology has provided a wide venue of expression systems for the recombinant
protein production. Recombinant GLP-1 has been produced in both yeast and E. coli
as a multimer (fused tandem repeat of itself) with enhanced stability (Hou et al.,
2007a, b). However, expensive and sophisticated fermentation facilities are required
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to scale-up the production.

Yasuda and colleagues (2006) reported a synthesis of

rice-derived GLP-1 pentamer, but it failed to retain the original protein function. In
another study, recombinant GLP-1 fused to globulin protein was generated in riceseed (Sugita et al., 2005). However, the activity of GLP-1 was detected only when
the fusion partner was cleaved by enzymatic digestion.
Synthesis of hTf has been investigated in bacteria, yeast, insect cells and
mammalian cell cultures (Funk et al., 1990; Steinlein and Ikeda, 1993; de Smit et al.,
1995; Ali et al., 1996; Mason et al., 2001; Sargent et al., 2006). As described in
section 1.1, these systems are not suitable for large-scale production of proteins at
low cost.
Previously, our lab has successfully produced recombinant GLP-1 decamer
and recombinant hTf in transgenic tobacco plants (Brandsma et al., 2009, 2010).
Plant-derived GLP-1 decamer was stably accumulated in tobacco and maintained its
insulinotropic property, although with reduced efficacy. Recombinant hTf showed
stable accumulation level in transgenic tobacco and retained many of the biological
functions of native hTf.
Most recently, generation of hTf fusion proteins were explored. Recombinant
GLP-1 - hTf and Ex-4 - hTf were produced in yeast (Kim et al., 2010). These fusion
proteins retained the ability of GLP-1 and Ex-4 to stimulate insulin secretion both in
vivo and by pancreatic islet cells in vitro. Nevertheless, the limitations of
conventional bioreactors, i.e. yeast, prompt the search for alternative production
source for hTf-fusion proteins.
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1.6

Hypothesis and research objectives
The purpose of this thesis was to investigate a novel plant-based production

strategy for the synthesis of recombinant fusion proteins, GLP-1 - hTf and Ex-4 hTf. It is hypothesized that transgenic tobacco will be capable of independently
accumulating GLP-1 - hTf and Ex-4 - hTf following subsequent transformation with
plant expression vectors. Furthermore, plant-derived GLP-1 - hTf and Ex-4 - hTf
are hypothesized to retain their native biological functions. The long-term goal of
this project is to develop a robust plant-based system for complex anti-diabetic
therapeutics which can be orally administered and effectively delivered to target cells
in T2DM patients. The specific objectives of the project were:
(1) To test the feasibility of producing GLP-1 - hTf and Ex-4 - hTf fusion
proteins in tobacco plants. To date, G L P -1-hT f and Ex-4 - hTf fusion
proteins have been expressed in yeast system but never been demonstrated
to synthesize in any transgenic plant systems. With this purpose in mind,
fusion gene constructs were designed for their constitutive expression.
Agrobacterium-mediated method was used to transform tobacco plants.
The resulting transgenic plants were analyzed for the presence of
recombinant fusion proteins. It was expected that GLP-1 - hTf and Ex-4 hTf could accumulate at a detectable levels in transgenic tobacco lines.
(2) To examine the biological activities of plant-derived recombinant
GLP-1 - hTf and Ex-4 - hTf fusion proteins via in vitro assays. The
functionalities of plant-derived GLP-1 - hTf and Ex-4 - hTf were
determined by the induction of insulin secretion to test GLP-1 and Ex-4
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and by cellular internalization to test hTf portion of the fusion proteins. It
was expected the plant-derived proteins would retain their original
biological activities.
(3) To determine the stability of GLP-1 - hTf and Ex-4 - hTf
proteins in GI environment in vitro.

fusion

The survival of recombinant

proteins is important when the proteins are meant for oral administration.
Recombinant fusion proteins were subjected to simulated gastrointestinal
fluids which mimic the acidic conditions of the digestive system. It was
expected that the fusion proteins would remain intact after incubation with
SGF (used to mimic the acidic stomach environment) and SIF (used to
mimic the intestine condition).
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Chapter 2
Methods and Materials

2.1

Bacterial Strains
All manipulations and propagations of plasmid DNA to build the expression

cassettes were carried out using the E. coli strain DH5a (Invitrogen, Burlington,
Ontario). The cell lines were maintained on Luria Bertani (LB) media (1% (w/v)
tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl) containing 1.5% (w/v) agar and
appropriate selective antibiotics as specified. Liquid cultures of DH5a cells used for
plasmid DNA extractions were grown in Terrific Broth (TB) (1.2% (w/v) tryptone,
2.4% (w/v) yeast extract, 0.4% (w/v) glycerol, 17 mM KH2P 0 4, 72 mM K2H P04).
Once expression cassettes were constructed, they were integrated into pBIlOl.l
binary vector, which allows for expression of the selectable marker (NPTII,
Kanamycin resistance) in both E. coli and tobacco plants. Due to the large size of the
binary vector backbone, the final DNA constructs were transformed into DH5a
electrocompetent cells because of their higher transformation efficiency relative to
calcium competent DH5a cells.
The Agrobacterium tumefaciens strain LBA4404 was employed for transient
expression assays and stable tobacco leaf disc transformation. The LBA4404 strain
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was maintained on Tryptone/Yeast extract/Calcium chloride (TYC) medium (1%
(w/v) tryptone, 0.5% (w/v) yeast extract, 0.066% (w/v) CaC12) containing 1.5% (w/v)
agar and rifampicin at 25 mg/ml. Liquid cultures of LAB4404 strain were grown in
TYC broth with rifampicin.
The antibiotics concentrations used for selection were as follows: E. coli cells
were selected for by resistance to carbenicillin at 100 pg/ml or kanamycin at 50
pg/ml; A. tumefaciens cells were selected for by resistance to kanamycin at 50 pg/ml
and rifampicin at 25 pg/ml.

2.2

Rapid Alkaline Lysis Mini-prep of plasmid DNA
Plasmid DNA was collected from bacterial strains by the alkaline mini-prep

procedure described by Bimboim and Doly (1979).

Briefly, cells from a single

colony were inoculated into 2 ml of TB containing the appropriate antibiotic. Cells
were grown overnight at 37°C while shaking. The following centrifugations were
done using a Sigma 1-15 centrifuge. A total of 1.5 ml cell culture was transferred
into an Eppendorf tube and centrifuged for 30 seconds at 12,000xg. The pellet was
resuspended in 100 pi GTE buffer (50 mM glucose, 25 mM Tris-HCl, 10 mM EDTA,
pH 8.0) and incubated on ice for 5 minutes.

After the incubation, 200 pi of

NaOH/SDS (0.2 M NaOH, 1% (w/v) SDS) was added into the solution, gently mixed
by inversion and incubated on ice for 5 minutes. Total of 150 pi of potassium acetate
(29.5% (w/v) glacial acetic acid, adjusted to pH 4.8 by KOH pellets) was then added
into the solution, mixed for 2 seconds by vortexing and placed on ice for 5 minutes.
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After centrifugation at 12,000xg for 5 minutes, the supernatant was collected, mixed
with 600 pi isopropanol and then incubated at room temperature for 5 minutes.
Plasmid DNA was precipitated by a 5 minute spin at 12,000xg and washed with 1 ml
of 70% (v/v) ethanol. The resulting plasmid DNA pellet was vacuum dried and
resuspended in 50 pi of double distilled water (ddH20 ) or TE buffer (10 mM TrisHC1, 1 mM EDTA, pH 8.0) and 1 pi RNase (Fermentas, Glen Bumie, Maryland)

2.3

Polymerase Chain Reaction (PCR)
PCR was used to facilitate cloning of all cDNA into plasmids by

incorporating the specific restriction enzyme recognition sites in the primers. This
technique was also used for screening the large populations of possible tobacco
transformants. All primers are outlined in Table 2. Approximately 50-100 ng of
template DNA was used for each 50 pi reaction. Each reaction mixture included lOx
PCR buffer, 2 M dNTP, 1 M of both forward and reverse promers, 2.5 mM MgCl2
and 1 unit of DNA polymerase.

High fidelity polymerase {pfu polymerase from

Fermentas) was used in all PCR reaction except for large screening, in which Taq
DNA polymerase (Fermentas) was applied in place of pfu. For screening purposes,
controls included untransformed plant gDNA in the place of transgenic plant gDNA,
or contained no template DNA or no primers to ensure that the primers or gDNA was
not contaminated, respectively.
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2.4

DNA Ligations
All DNA ligations were performed with the Rapid Ligation kit (Fermentas). A

total of 20 pi ligation mixture contained 3 pg of insert DNA, 1 pg of backbone
plasmid DNA, 4 pi of 5x reaction buffer, 1 pi T4 DNA ligase and topped up with
ddH20 . After 10 to 15 min incubation at room temperature, 3-7 pi of the mixture
was transformed into chemically competent DH5a cells (Invirtogen) by heat shock or
into electrocompetent DH5a cells by electroporation.

The preparation of

electrocompetent cells were described previously by Miller and Nickoloff (1995).

2.5

E. coll Transformation
Chemically competent DH5a cells were transformed with plasmid DNA by

heat shock transformations. In brief, approximately 50 ng of plasmid DNA was
added to 40 pi DH5a cells, gently mixed and placed on ice for 35 min. The cells
were then heat shocked in a 37°C water bath for 5 min and incubated on ice for 10
min before transferred to a tube containing 800 pi SOC media (0.5% (w/v) yeast
extract, 2% (w/v) tryptone, 10 mM NaCl, 2.5 mM KC1, 10 mM MgCl2, 10 mM
M gS04, 20 mM glucose). After 1 hour incubation at 37°C with shaking at 200 rpm,
200 pi of the culture was spread onto LB agar plates with appropriate antibiotics.
Electrocompetent DH5a cells were transformed with plasmid DNA by
electroporation (Miller and Nickoloff, 1995). Briefly, 1 or 2 pi ligation mixture was
mixed with 40 pi electrocompetent cells and incubated on ice for 1 min. The mixture
was then transferred to a cold electroporation cuvette and placed in the chamber slide
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of MicroPulser™ electroporation apparatus (Bio-Rad Laboratories). The cells were
pulsed once in the electroporation apparatus. A total of 1 ml of SOC medium was
added to the cuvette after the pulse and the cells were gently resuspended. The
resulting cell suspension was incubated at 37°C for 1 hour, shaking at 200 rpm. A
total of 50 pi of the culture was spread onto LB agar plates with appropriate
antibiotics.

2.6

Construction of plant expression vectors
PCR was used to facilitate cloning of all cDNA into plasmids by

incorporating the desired restriction enzyme recognition sites in the primers. The
primers used for the vector construction are listed in Table 2.

The construction

scheme is illustrated in Figure 2. All PCR products were subcloned into appropriate
vectors and transformed into DH5a cells according to E. coli transformation methods
described in Section 2.5.

2.6.1 Construction of GLP-1 - hTf plant expression vector
The plasmid containing GLP-1 gene was provided by Dr. Ma’s laboratory.
The GLP-1 cDNA was amplified by PCR using the forward primer GLP-1-F and the
reverse primer GLP-1-R (Table 1). The forward primer GLP-1-f contained Ncol
restriction site (underline) at the start codon and it incorporated barley a-amylase
signal peptide (bold) immediately upstream of the GLP-1 sequence. The reverse
primer GLP-1-R contained Seal restriction site (underlined) for creating a fusion site,

Table 1.

PCR Primers

Primer Name

Nucleotide sequence (5’ ->3’)

Purpose

GLP-l-F

ACCATGGGGAAGAACGGCAGCCTGTGCTGCTTCTCTCTGCTGCTGCTG
CTGCTTCTCGCCGGGTTGGCGTCCGGGCATTCTGAGGGAACCTTCACC

Cloning

GLP-l-R

GACAGTACTTCCGCCGCCArrcGAcrrACCTCCGCCCGAGCCACCGcc
ACCCCTTCCCTTCA CCAA CCAA GC

Cloning

Ex-4-F

ACCATGGGGAAGAACGGCAGCCTGTGCTGCTTCTCTCTGCTGCTGCTG
CTGCTTCTCGCCGGGTTGGCGTCCGGGCATGGTGAGGGTACCTTCACC

Cloning/S creening

Ex-4-R

AATTTCTAGATTAA TGA TOATGA TGA TGA TGAGAAGGTGGAGGA
GC

Cloning

hTf-Fl

GG^GCrCCrCC/4CC7GGTGGCGGTGGCTCGGGCGGAGGTGGGTCGGGT
GGCGGCGGATCAGTCCCTGATAAAACTGTGAGATGG

Cloning

hTf-F2

GGCGGAAGT ACTGTCCCTGATAAAACTGTGAGATGG

Cloning

hTf-R

AATCTAGATT AAAGCTCA TCCTTATGATGATGATGATGATGAGGTCTACGGA
AAGTGCAGGC

Cloning/S creening
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flexible linker sequence (bolded) and last 21 nucleotide of GLP-1 sequence. PCR
reaction was performed under following conditions: denature at 95°C for 55 s, anneal
at 65°C for 47 s and elongate at 72°C for 1 min, for a total of 35 cycles followed by a
final elongation at 72°C for lOmin.
The h T f cDNA clone was obtained from OriGene (Rockville, MD, USA).
The coding region, excluding the native hT f signal peptide sequence, was amplified
using forward primer hTf-F2 and reverse primer hTf-R. Forward primer hTf-F2
contained the last 12 nucleotides from 3’ end of flexible linker sequence which has
Seal site (underline) for fusion with h T f sequence. Reverse primer hTf-R contained 3’
Hisx6 tag (double underline), ER-retention signal KDEL (italics), stop codon (bold)
and Xbal restriction site (underline). PCR reaction was performed under following
conditions: denature at 94°C for 45 s, anneal at 55°C for 45 s and elongate at 72°C
for 2 min, for a total of 35 cycles followed by a final elongation at 72°C for lOmin.
The amplified GLP-1 and hT f sequences were blunt-end ligated into the Smal site of
pUC19 vector and subsequently sequenced to confirm the sequence integrity
(Sequencing Facility; Robarts Research Institute, London, ON, Canada).
To create the fusion expression cassette, GLP-1 sequence was released from
pUC19 as Ncol/Scal fragment and h T f sequence was released as Seal/Xbal fragment
then inserted into pRTL-2 vector using three-fragment ligation (Figure 2).

The

resulting expression cassette contained the enhanced constitutive cauliflower mosaic
virus (CamV) 35S promoter, tobacco etch virus (TEV) 5’UTL, barley a-amylase
signal peptide, GLP-1 - linker - hTf fusion sequence, a Hisx6 tag for protein
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Figure 2.
Construction scheme of expression vector p B I 101.1 - GLP-1 - h T f and p B I
101.1 - Ex-4 - hTf. (A) The coding sequences of GLP-1 or Ex-4 were amplified by
PCR using primers that incorporated barley a-amylase signal peptide (SP) sequence
at the 5’ end. The coding sequence of hT f was amplified by PCR using primers that
incorporated linker (L) sequence. (B ) Each amplified sequences were placed into
pUC19 which were then cleaved and ligated into the pRTL2 vector containing
promoter and terminator sequences. (C) The internal Xba I site was destroyed by
Klenow treatment then the expression cassette was place into the intermediate
pBluescript to allow proper integration of the entire cassette into final binaiy vector.
(D) The expression cassette was ligated into the multiple cloning site in the T-DNA
region of plant binary vector pBI 101.1.
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Figure 3.
Schematic diagram of plant expression vector. The T-DNA region inserted into
the plant genome contains the nopaline synthase (NPT-II) expression cassette, which
confers kanamycin resistance on transformed cells.

The vector contains NPT-II

promoter (P nosX NPT-II terminator (TNOS), left border (LB) and right border (RB).
The transgene was driven by Cauliflower Mosaic Virus 35S promoter (CaMV 35S)
with a double enhancer sequence. The expression cassette also includes tobacco etch
virus leader sequence (TEV), barley a-amylase signal peptide (SP), linker sequence
(L), 6xHis tag and ER retention signal (KDEL).
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purification, KDEL signal for ER retention and the nopaline synthase (NOS)
terminator (Figure 3). The Xbal site in pRTL-2 - GLP-1 - hTf was destroyed by
Klenow treatment for fusion purpose.

This vector was digested with Sphl then

treated with Klenow to produce a blunt-ended fragment, which was ligated into
pBluescript at Smal site. The entire expression cassette was released from pBluscript
by using Sail and Xbal digestion then cloned into the final plant binary vector
pBI 101.1 to produce pBI 101.1 - GLP-1 - hTf (Figure 2).

2.6.2 Construction of Ex-4 - hTf plant expression vector
The cDNA of Ex-4 was provided by Dr. Ma’s laboratory and amplified using
designed forward primer Ex-4-F and reverse primer Ex-4-R (Table 1). Forward
primer Ex-4-F contained Ncol restriction site (underline) at the start codon and it
incorporated barley a-amylase signal peptide (bold) immediately upstream of the Ex4 sequence which replaced the native Ex-4 signal peptide sequence. Reverse primer
Ex-4-R contained 3’ Hisx6 tag (italics), stop codon (bold) and Xbal restriction site
(underline). PCR reaction was performed under following conditions: denature at
94°C for 45 s, anneal at 55°C for 45 s and elongate at 72°C for 45 s, for a total of 35
cycles followed by a final elongation at 72°C for lOmin.
The hT f cDNA clone was obtained from OriGene (Rockville, MD, USA).
The coding region, excluding the native hT f signal peptide sequence, was amplified
using forward primer hTf-Fl and reverse primer hTf-R. Forward primer hTf-Fl
contained the last 14 nucleotides from 3’ end of Ex-4 sequence (italics) which has
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S a d site (underline) for fusion and incorporated a linker sequence (bold) upstream of
hT f sequence. Reverse primer hTf-R contained 3’ Hisx6 tag (double underline), ERretention signal KDEL (italics), stop codon (bold) and Xbal restriction site
(underline). PCR reaction was performed under following conditions: denature at
94°C for 45 s, anneal at 55°C for 45 s and elongate at 72°C for 2 min, for a total of
35 cycles followed by a final elongation at 72°C for lOmin. The amplified Ex-4 and
h T f sequences were blunt-end ligated into the Smal site of pUC19 vector and
subsequently sequenced to confirm the sequence integrity (Sequencing Facility;
Robarts Research Institute, London, ON, Canada).
To create the fusion expression cassette, Ex-4 sequence was released from
pUC19 as Ncol/Sac I fragment and h T f sequence was released as Sad!Xbal fragment
then inserted into pRTL-2 vector using three-fragment ligation.

The resulting

expression cassette contained the enhanced constitutive cauliflower mosaic virus
(CamV) 35S promoter, tobacco etch virus (TEV) 5’UTL, barley a-amylase signal
peptide, Ex-4 - linker - hTf fusion, a Hisx6 tag for protein purification, KDEL signal
for ER retention and the nopaline synthase (NOS) terminator (Figure 3). The Xbal
site in pRTL-2 - Ex-4 - hTf was destroyed by Klenow treatment for fusion purpose
(Figure 2). This vector was digested with Sphl then treated with Klenow to produce
a blunt-ended fragment, which was ligated into pBluescript at Smal site. The entire
expression cassette was released from pBluscript by using Sail and Xbal digestion
then cloned Pinto the final plant binary vector pBIlOl.l to produce pBIlOl.l - Ex-4
- hTf (Figure 3).
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2.7

Generation of transgenic plants
The engineered plant expression vector pBI101.1-Ex-4-hTf was first

introduced into A. tumefaciens strain LBA4404 by tri-parental mating using helper
plasmid pRK4013.

Stable nuclear transformation was performed in order to

transform low-alkaloid Nicotiana tobacum cv.81V9 by co-cultivating leaf discs with
A. tumefaciens LBA4404 containing the plant expression vector according to the
method of Horsch et al. (1985). Transgenic plants were selected on Murashige and
Skoog (MS) medium containing 100 mg/L kanamycin. As the transgenic plants
matured, they were transferred into green house and maintained for further analysis.
Transient expression of Nicotiana benthamiana was performed according to
the method of Sparkes et al. (2006). Briefly, A. tumefaciens LBA4404 containing the
plant expression vector and A. tumefaciens containing p i9 were inoculated and
grown overnight at 28°C. Cells were harvested and resuspended in infiltration media
(50 mM MES, 2 mM Na3P 0 4T2H20 , 0.0001 M acetosyringone). The diluted cell
culture (OD60o = 0.5) was injected into the leaves of 6-week-old N. benthamiana
plants. The transformed leaves were harvested each day for seven days and proteins
were extracted for analysis.

2.8

Screening of putative transgenic plants using PCR
Total genomic DNA was extracted from individual transgenic tobacco lines

using a basic phenol/chloroform extraction (Ma et al. 2005). In brief, tobacco leaf
tissue was homogenized in DNA extraction buffer [0.2 M Tris-HCl (pH 7.5), 0.25 M
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NaCl, 25 mM EDTA, 0.5% (w/v) SDS] and incubated at room temperature for 1 hour.
The sample was centrifuged for 10 min at 12,000xg and supernatant was collected.
Sodium acetate (3 M CH3COONa, pH 4.8) and phenol/chloroform (1:1) was added
to the supernatant then the mixture was centrifuged for 5 min at 12,000xg. The
aqueous phase was extracted once with 100% isopropanol and the resulting DNA
pellet was washed with 70% ethanol. Extracted DNA was used as template for PCR
analysis to confirm the integration of Ex-4 - hT f fusion. The primer pair EX-4-F and
hTf-R was used under same PCR conditions as describe above. All PCR products
were analyzed by electrophoresis on a 7.5% (w/v) agarose gel.

2.9

Tobacco RNA extraction and RT-PCR analysis
Total RNA was prepared from transgenic tobacco leaf tissue by using a Trisol

RNA extraction kit (Invitrogen) according to the manufacturer’s recommendations.
Extracted RNA was transcribed into cDNA with Superscript II Reverse
Transcriptase following the manufacturer’s protocol (Invitrogen). Briefly, 5 pg of
total RNA extracted from individual plants, 1 pi Oligo(dT) (500 pg/pl), 1 pi dNTP
mix (10 mM each) and 5 pi sterile distilled water were mixed and incubated at 65 °C
for 5 min.

Following the addition of 4 pi First-Strand Buffer and 2 pi 0.1 M

Dithiothreitol (DTT), the reaction mixture was further incubated for 2 min at 42 °C.
After incubation, 1 pi of Superscript II Reverse Transcriptase was added and
incubated at 42 °C for 50 min to produce cDNA. PCR analysis was performed using
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primer pair EX-4-F and hTf-R under same PCR conditions as describe above. All
PCR products were analyzed by electrophoresis on a 7.5% (w/v) agarose gel.

2.10

Accumulation of GLP-1 -h T f and Ex-4 - hTf in transgenic plants
Positive transgenic plants confirmed by PCR analysis were analyzed to

determine the recombinant protein accumulation level using SDS-PAGE followed by
Western blotting.

In brief, tobacco leaf tissues were homogenized in protein

extraction buffer [25 mM Tris-HCl (pH 7.0), 50 mM NaCl, 2mM (J-niercaptoethanol,
ImM phenyl-methysulfonyl fluoride (PMSF), 2 pg/mL aprotinin, 2 pg/mL pepstain
A and 2 pg/mL leupeptin]. Samples were centrifuged at 13,000xg for 10 min at 4°C
and supernatant was collected. Protein concentration was measured by the method of
Bradford (1976) using the Bio-Rad protein dye reagent (Bio-Rad, Hercules, CA,
USA), and bovine serum albumin (BSA) as standard (Sigma-Aldrich Canada). The
expression of recombinant GLP-1 - hTf and Ex-4 - hTf fusion proteins were
analyzed by Western blotting.

First, protein extracts were boiled for 10 min in

sample buffer [0.0063 M Tris-HCl, 2% (w/v) SDS, 10% (v/v) glycerol, 0.1 M DTT,
0.01% (w/v) bromophenol blue (pH 6.8)] and separated by 10% SDS-PAGE then
subsequently blotted onto polyvinylidene difluoride (PVDF) membranes (Millipore,
Burlington, Massachusetts).

The membrane was blocked for 1 hour at room

temperature in 5% (w/v) skim milk-TBS-T [20 mM Tris, 150 mM NaCl, 0.02% (v/v)
Tween-20 (pH 10)], washed with TBS-T. The membrane was incubated over night
at 4°C with goat anti-hTf primary antibody (Sigma-Aldrich Canada, Oakville,
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Ontario) diluted 1:500 (v/v).

The membrane was washed again by TBS-T and

incubated with horseradish peroxidise conjugated swine anti-goat secondary antibody
(Sigma-Aldrich Canada, Oakville, Ontario) for 1 hour.

Immunodetection was

performed using the enhanced chemiluminescence (ECL) detection system (Perkin
Elmer Life Sciences, Rockford, IL) according to the manufacturer’s protocol.

2.11

Quantification of plant-derived GLP-1 - hTf and Ex-4 - hTf
The accumulation of GLP-1 - hTf and Ex-4 - hTf fusion protein in crude

tobacco leaf extract was quantified using an enzyme linked immunosorbent assay
(ELISA).

The accumulated recombinant protein was compared against known

quantities of hTf reference protein (Sigma-Aldrich) as a standard.

The serial

dilutions of standard hTf as well as crude tobacco extracts, in triplicates, were
resuspended in sodium bicarbonate buffer (pH9.6) and coated onto a 96-well
microtiter plate then incubated at 4°C for overnight. Wells were washed three times
with PBS-T [lx phosphate buffered saline containing 0.05% (v/v) Tween-20] and
blocked with 3% (w/v) BSA in PBS-T for 3 hours at room temperature.

After

washing with PBS-T, goat anti-hTf monoclonal antibody (Sigma-Aldrich) diluted to
1:2000 (v/v) was added to each well and incubated overnight at 4°C. Following five
subsequent PBS-T washes, horseradish peroxidise-conjugated swine anti goat IgG
antibody diluted to 1:2000 (v/v) was added to each well and incubated for 1 hour at
room temperature.

The plate was washed eight times with PBS-T, and then

tetramethyl benzidine (TMB) substrate (R&D Systems) was added according to the
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manufacturer’s protocol and incubated in the dark for 30 min at room temperature.
The substrate reaction was stopped by adding 50 pL/well stop solution (1 M H2S 04).
The plate was read as an optical density (OD) value measured at 450 nm in a
microplate reader (Bio-Rad 3550).

The OD measurement was converted as a

percentage of total soluble protein by reference to an ELISA standard curve
constructed with the hTf reference protein.

2.12

Purification of His-tagged GLP-1- hTf and Ex-4 - hTf
Plant-derived GLP-1- hTf and Ex-4 - hTf fusion proteins were purified from

leaf extracts of transgenic tobacco plants with histidine affinity chromatography
using

HiTrap

Chelating HP

columns (GE Healthcare)

according to the

manufacturer’s instructions. In brief, the leaf samples of tobacco plants were grinded
in liquid nitrogen to a fine powder and homogenized in protein extraction buffer [25
mM Tris-HCl (pH 7.0), 50 mM NaCl, 2mM P-mercaptoethanol, ImM phenylmethysulfonyl fluoride (PMSF), 2 pg/mL aprotinin, 2 pg/mL pepstain A and 2
pg/mL leupeptin] in a 1:4 (w/v) ratio of sample to buffer. The homogenate was
filtered through a filter paper and centrifuged at 14,000 g for 10 min at 4°C.
Supernatant was collected and centrifuged again at 14,000 g for 10 min at 4°C. The
final supernatant was filtered through a 0.45 pm membrane filter and loaded into the
prepared HiTrap Chelating HP column and washed with wash buffer (2 mM
imidazole, 20 mM Na2H P04, 500 mM NaCl) to remove nonspecifically bound
tobacco leaf endogenous proteins. The bound GLP-1- hTf and Ex-4 - hTf fusion
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protein was eluted with elution buffer [500 mM imidazole, 20 mM Na2H P04, 500
mM NaCl] with 1-mL fractions collected for further analysis. The eluted GLP-1hTf and Ex-4 - hTf fractions were dialyzed extensively against lx PBS (pH 7.5) and
concentrated using speed vacuum at 4°C. ELISA was carried out to quantify the
amount of fusion protein using hTf reference protein as a standard.

2.13

Insulin induction assay
The functionality of plant-derived GLP-1 - hTf and Ex-4 - hTf fusion

proteins was determined by its ability to stimulate insulin secretion from a mouse
pancreatic beta-cell line, MIN6 cells, according to the method of Miyazaki et al.
(1990) with minor modifications. Briefly, MIN6 cells were cultured and maintained
in 25 cm2 tissue culture flasks using high-glucose Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 15% (v/v) fetal calf serum, 100 U/mL
penicillin, 0.1 mg/mL streptomycin, and 2 mM L-glutamine at 37°C in an
atmosphere of humidified air (95%) and C 0 2 (5%).

The culture medium was

replaced with fresh medium every 24 hours and cells were used for the experiments
once they had reached 80% confluence. To determine the insulin-induction effect of
plant-derived GLP-1- hTf and Ex-4 - hTf fusion proteins on MIN6 cells, the cells
were washed with PBS and harvested using Trypsin-EDTA solution (0.125 M trypsin,
0.05 mg/ml EDTA) for 3 to 5 min. Harvesting was stopped with the addition of
DMEM and subsequent centrifugation (1,500 rpm for 5 min).

Cell pellets were

resuspended in 10% (v/v) DMEM containing 10 mM glucose and counted using
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hemacytometer.

Cells were then added to each 1.5 mL culture tube (~ lx l0 6

cells/tube) containing 1.2 mL 10% (v/v) DMEM medium in the presence of 10 mM
glucose. The insulin-induction effect of plant-derived GLP-1- hTf and Ex-4 - hTf
fusion proteins were compared to commercial GLP-1 standard (Sigma) and DMEM
only, and 200 ng/ml of each protein were added to the prepared MIN6 cell plates.
Various concentrations of glucose (0, 5, 10, 25 mM) were added to each plate. MIN6
cells were incubated for 135 min at 37°C, with culture supernatants subsequently
collected and assayed for insulin concentration using an insulin ELISA kit (Crystal
Chem Inc., Downers Grove, IL, USA) according to the manufacturer’s protocols.

2.14

Detection of internalized plant derived GLP-1- hTf and Ex-4 - hTf
Human intestinal epithelial cell line, Caco-2 cells, was used to determine the

internalization of plant-derived GLP-1 - hTf and Ex-4 - hTf fusion proteins in vitro.
Caco-2 cells were grown to the density of 0.5x106 cells/flask then maintained in fresh
10% (v/v) FBS-RPMI 1640 medium (Invitrogen). The cells were inoculated into
60x15 mm petri dishes as triplicates and incubated at 37°C in an atmosphere of 5%
C 0 2 and 95% air for 24 hours. After the incubation, the medium was removed and
the cells were washed twice the serum-free F12 medium. Following the wash, the
cells were incubated in serum-free F12 medium at 37°C in an atmosphere of 5% C 0 2
and 95% air for 1 hour to starve the cells. Two different concentration (0.2 and 1
pg/mL) of commercial hTf standard (Sigma), plant-derived hTf, GLP-1- hTf and and
Ex-4 - hTf proteins were added to Caco-2 cells and incubated for another 1 hour with
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the same condition. To stop the reaction, the plates were placed onto ice and washed
with cold Dulbecco’s-PBS to remove excess and unbound proteins.

The cell

membrane-bound proteins were removed using acid buffer [200 mM acetic acid, 500
mM NaCl, pH 4.5] by incubating for 5 min on ice then washed twice with cold
Dulbecco’s-PBS to neutralize the pH. The cells were removed from the dish using
plastic scraper and place into 15 mL conical tubes. The cell pellet was collected by
centrifugation for 5 min at 14,000 g, then cells were lysed with lysis buffer [1% (v/v)
Triton X-100, 50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 10 mM NaF, 1 mM
vanadate, 1:100 (v/v) phosphatise inhibitor cocktail, pH7.4] (Sigma-Aldrich) by 10
min incubation on ice. The cell lysate was centrifuged at 10,000 g at 4°C for 10 min
to remove cellular debris.

The supernatant was collected and its protein

concentration determined by ELISA followed by Western blotting using anti-hTf
antibody

2.15

Digestion of GLP-1- hTf and Ex-4 - hTF in SGF and SIF
The stability of plant-derived GLP-1- hTf and Ex-4 - hTf fusion protein was

determined by SGF and SIF digestion testing according to Tremblay et al. (2011).
Briefly, His-purified protein sample was incubated in SGF (0.2 g NaCl, 0.32g pepsin,
700 p.L HC1, in 100 mL dH20 , pH 2.5) and SIF (0.68 g monobasic KH2P04, 7.7 mL
0.2 M NaOH, 1.0 g pancreatin , in 100 mL dH20 , pH ~6.8) at 37°C. The digestion
was stopped by a neutralization buffer (3.4 g Na2C 0 3 in 100 mL dH20 ) at time 0, 15
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s, 30 s, 1 min, 5 min, 15 min, and 30 min. The neutralized samples were boiled for
10 min and analysed using immunoblot analysis.

2.16

Immunoblot analysis of SGF and SIF

The proteins were boiled for 10 min in 5x sample buffer [0.0063 M Tris-HCl, 2%
(w/v) SDS, 10% (v/v) glycerol, 0.1 M DTT, 0.01% (w/v) bromophenol blue (pH 6.8)]
and separated by 10% SDS-PAGE then subsequently blotted onto polyvinylidene
difluoride (PVDF) membranes (Millipore, Burlington, Massachusetts).

The

membrane was blocked for 1 hour at room temperature in 5% (w/v) skim milk-TBST [20 mM Tris, 150 mM NaCl, 0.02% (v/v) Tween-20 (pH 10)], washed with TBS-T.
The membrane was incubated over night at 4°C with goat anti-hTf primary antibody
(Sigma-Aldrich Canada, Oakville, Ontario) diluted 1:500 (v/v). The membrane was
washed again by TBS-T and incubated with horseradish peroxidise conjugated swine
anti-goat secondary antibody (Sigma-Aldrich Canada, Oakville, Ontario) for 1 hour.
Immunodetection was performed using the enhanced chemiluminescence (ECL)
detection system (Perkin Elmer Life Sciences, Rockford, IL) according to the
manufacturer’s protocol.

2.17

Statistical analysis
All statistical analysis was completed independently in triplicate. A paired

two-tailed Student’s i-test was used to determine whether or not differences between
samples were significant. Values of p < 0.05 were held to be significant.
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Chapter 3
Results

3.1

Construction of plant expression vectors pBIlOl.l - GLP-1 - hTf and

pBIlO l.l - Ex-4 -hTf.
The construction of plant expression vectors pB IlO l.l - GLP-1 - hT f and
pB IlO l.l - Ex-4 - hT f is explained in section 2.6 and shown in Figure 2. The
resulting plant binary vectors were digested with Sail and Xbal to confirm their
proper integration. The digestion of pB IlO l.l - GLP-1 - hT f produced 3.35 kb
fragment and the digestion of pB IlO l.l - Ex-4 - hT f produced 3.37 kb fragment
which correspond to the correct size of each expression cassette (Figure 4). Both
expression cassettes were under the control of enhanced constitutive cauliflower
mosaic virus (CaMV) 35S promoter and contained tobacco etch virus (TEV) 5’UTL,
barley a-amylase signal peptide, GLP-1/Ex-4 - linker - hT f fusion sequence, a Hisx6
tag for protein purification, KDEL signal for ER retention and the nopaline synthase
(NOS) terminator (Figure 3).

3. 2

Production of transgenic tobacco plants

3.2.1

Production of Ex-4 - hTf in transgenic tobacco plants by stable nuclear

transformation
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Figure 4.
Confirmation of plant binary vector containing expression cassettes. The final
binary vector was confirmed by restriction enzyme digestion. Both binary vectors,
pBIlOl. 1 - GLP-1 - h T fm d pBIlOl. 1 Ex-4 -h T f, were digested with Sal I and Xba I
to test for proper integration of the expression cassettes.
subjected to same digestion as a negative control.

Empty pB IlO l.l was

Marker
(bp)
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Low-nicotine and low alkaloid N. tabacum cultivar 81V9 was transformed
with A. tumefaciens strain LBA4404 containing plasmid pB IlO l.l - Ex-4 - hT f by
tobacco leaf-disc transformation described by Horsch et al. (1985).

Total of 10

independent transgenic tobacco lines were produced. All transgenic plants showed
normal growth and there were no morphological differences between transgenic and
untransformed control plants. The presence of the Ex-4 - h T f fusion gene in the plant
genome was verified by PCR. A DNA fragment of expected size (~2.3 kb) was
amplified in all transgenic lines (Figure 5 A and B). Furthermore, PCR-positive
tobacco plants were analyzed at transcript level using RT-PCR. Total extracted plant
RNA was used as a template. The result revealed the presence of a DNA fragment of
expected size (~2.3 kb) in all ten of the transgenic tobacco plants, but not in
untransformed wild type plant (Figure 5 C and D). PCR amplification of all samples
of extracted tobacco plant RNA without first-strand cDNA synthesis produced no
fragments, which eliminated the possibility of DNA contamination of the RNA
samples (data not shown). This suggests that the plant transformation was successful
and confirmed the integration of Ex-4 - hT f fusion gene in the plant genome.

3.2.2

Production of GLP-1 - hTf and Ex-4 - hTf in tobacco plants by transient

expression
The engineered plant expression vector pB IlO l.l - GLP-1 - hT f ox pB IlO l.l
- Ex-4 - h T f was introduced into A. tumefaciens strain LBA4404 by tri-parental
mating using helper plasmid pRK4013. Six-week-old N. benthamiana plants were
infiltrated with the A. tumefaciens clone containing pB IlO l.l - GLP-1 - hT f

or
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Figure 5.
Detection of Ex-4 - hTf in transgenic tobacco plants by PCR and RT-PCR
analysis.

Total genomic DNA and RNA was extracted from the leaves of ten

transgenic tobacco lines transformed with pB IlO l.l - Ex-4 - hTf. (A and B) The
genomic DNA was then used for PCR amplification in the presence of transgene
specific primers.

The resulting PCR products were analyzed by agarose gel

electrophoresis. Total of 45 plants were examined and ten independent transgenic
lines showed the successful integration of transgene. (C and D) The isolated RNA
was reverse transcribed to synthesize cDNA templates. Primers specific for Ex-4 hT f sequence were used for amplification of cDNA templates.

As a positive control

(+), pRTL2 - Ex-4 - hTf vector was used as a template and genomic DNA from
untransformed wild type 81V9 tobacco plant was used as a negative control (WT).
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pB IlO l.l - Ex-4 - hT f together with cultures of A. tumefaciens containing the pl9
expression cassette, a viral inhibitor of post-transcriptional gene silencing in plants
that has proven effective in increasing the yield of transiently expressed proteins
(Lakatos et al. 2004). Leaf samples were collected from infiltrated plants from 1-7
days after infiltration (DAI) with four different concentrations of A. tumefaciens
cultures, with an equal amount of p i 9 added for each assay. The tobacco-derived
proteins from leaves were extracted for protein analysis (Figure 6 and 7).

3. 3

Accumulation of recombinant proteins in transgenic plants

3.3.1 Accumulation of GLP-1 - hTf protein in tobacco plants
The accumulation of GLP-1 - hTf protein in transgenic plants was examined
and verified with SDS-PAGE followed by Western blotting. All N. benthamiana
plants infected with Agrobacterium concentrations (A60o) of 0.1, 0.25, 0.5, and 0.75
were subjected to the analysis. Probing of total extracted tobacco plant TSP with
goat anti-hTf monoclonal antibody (Sigma-Aldrich Canada) identified a single ~ 80
kDa molecular weight band corresponding to the size of GLP-1 - hTf (Figure 6A-D).
The difference in expression level can be seen in transiently transformed N.
benthamiana plants at each day after infiltration.

As expected, no bands were

detected from TSP extracted from untransformed wild-type N. benthamiana plants
under identical conditions (Figure 6A-D). Plant-derived recombinant hTf, provided
by Dr. Ma’s laboratory, was used as a positive control (+) to assess the affinity of the
primary antibody.

44

Figure 6.
Western blot analysis and quantification of GLP-1 - hTf protein in transiently
transformed TV benthamiana.

The plants were infiltrated with Agrobacterium

containing pB IlO l.l - GLP-1 - hT f vector then leaves were harvested for 1 -7 days
after infection (DAI).

Total soluble protein was extracted from the leaves of

agroinfiltrated TV. benthamiana plants. Proteins were separated by 10% SDS-PAGE,
transferred onto a PVDF membrane and probed with goat anti-hTf primary antibody
followed by swine anti-goat secondary antibody. (A-D) Accumulation of GLP-1 hTf in plants infected with Agrobacterium concentrations (A600) of 0.1, 0.25, 0.5, and
0.75.

Plant-derived recombinant hTf was used as a positive control (+) and

untransformed wild type 81V9 tobacco plant was used as a negative control (WT).
Approximately 30 pg of TSP were loaded for each western blot experiments. (E)
ELISA data for GLP-1 - hTf accumulation in TV. benthamiana plant at optimal
Agrobacterium concentration (A60o - 0.5). Concentration levels are expressed as a
percentage of total soluble protein (% TSP). Data shown represents average value of
three independent experiments with error bars correspond to standard deviation.
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As shown in Figure 6E, the relative accumulation level of GLP-1 - hTf
protein in plant TSP extracts was determined using an indirect ELISA method with
goat anti-hTf monoclonal antibody (Sigma-Aldrich Canada), compared to a
commercially available hTf standard (Sigma-Aldrich Canada). The N. benthamiana
plants infected with Agrobacterium concentration (A60o) of 0.5 showed the highest
GLP-1 - hTf expression level at day 3 which reached 3.92% of plant TSP (Figure 6E)

3.3.2 Accumulation of Ex-4 - hTf protein in transgenic tobacco plants
The accumulation of Ex-4 - hTf protein in transgenic plants was examined
and verified with SDS-PAGE followed by Western blotting.

The difference in

expression levels can be seen in transiently transformed N. benthamiana plants at
each day after infiltration (Figure 7A).

Total of ten transgenic tobacco lines

successfully expressed Ex-4 - hTf protein (Figure 7C). Probing of total extracted
tobacco plant TSP with goat anti-hTf monoclonal antibody (Sigma-Aldrich Canada)
identified a single ~ 80 kDa molecular weight band corresponding to the size of Ex-4
- hTf (Figure 7A and C). As expected, no bands were detected from TSP extracted
from untransformed wild-type N. benthamiana plants and N. tobacum 81V9 plants
under identical conditions (Figure 7A and C).

Plant-derived recombinant hTf,

provided by Dr. Ma’s laboratory, was used as a positive control (+) to assess the
affinity of the primary antibody.
As shown in Figure 7B and D, the relative accumulation level of Ex-4 - hTf
protein in plant TSP extracts was determined with an indirect ELISA method using
goat

anti-hTf monoclonal antibody (Sigma-Aldrich Canada), compared to a
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Figure 7.
Western blot analysis and quantification of Ex-4 - hTf protein in tobacco plants.
(A) Total soluble protein was extracted from the leaves of agroinfiltrated N.
benthamiana plants. Highest protein concentration reached at day 6 in N.
benthamiana plant infected with A60o = 0.5 Agrobacterium concentration (*). (B)
ELISA data for Ex-4 - hTf accumulation in N. benthamiana plant at optimal
Agrobacterium concentration (A60o) of 0.5. (C) Total soluble protein was extracted
from the leaves of transgenic plants transformed with pBIlOl.l - Ex-4 - hTf.
Proteins were separated by 10% SDS-PAGE, transferred onto a PVDF membrane
and probed with goat anti-hTf primary antibody followed by swine anti-goat
secondary antibody. Approximately 55 pg of TSP were loaded for each transgenic
line. (B) Protein samples from each transgenic plant were used to determine the
accumulation level of Ex-4 - hTf using ELISA. Data shown represent average value
of three independent experiments with error bars correspond to standard deviation.
For Western blot analysis, plant-derived recombinant hTf - GLP1 protein was used
as a positive control (+) and untransformed wild type 81V9 tobacco plant was used
as a negative control (WT). For ELISA result, concentration levels are expressed as a
percentage of total soluble protein (% TSP).
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commercially available hTf standard (Sigma-Aldrich Canada). The N. benthamiana
plants infected with Agrobacterium concentration (A60o) of 0.5 showed the highest
Ex-4 - hTf expression level at day 5 which reached 4.2% of plant TSP (Figure 7B)
The level of Ex-4 - hTf accumulation in stably transformed N. tobacum 81V9 plants
was variable among individual transgenic lines, with highest accumulation in T30
plant with 0.27% TSP (Figure 7D).

3. 4

Glucose-dependent insulin secretion by tobacco-derived GLP-1 - hTf and

Ex-4 - hTf proteins
The primary therapeutic use of GLP-1 and its analogue Ex-4 is to enhance the
glucose-stimulated insulin secretion. With this in mind, plant-derived GLP-1 - hTf
and Ex-4 - hTf proteins were analyzed for their ability to stimulate insulin secretion
using a mouse pancreatic P cell line, MIN6. Our lab has previously developed a
GLP-1 fused at the C-terminal of hTf, known as hTf - GLP-1. For comparison
purpose, tobacco-made hTf - GLP-1 was included in insulin induction assay to
examine the difference in function compared to GLP-1 - hTf.

3.4.1 Effect of GLP-1 - hTf on insulin secretion
Purified GLP-1 - hTf protein, commercial GLP-1 standard (Sigma), and
plant-derived hTf - GLP-1 (200 ng/mL each) were incubated in solution with MIN6
cells and the increase in insulin concentration was assessed by a direct insulin ELISA
kit (Crystal Chem Inc.). As shown in Figure 8, the proteins were incubated with
MIN6 cells in the presence of various glucose levels (0 - 25 mM). Tobacco-derived
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hTf - GLP-1 protein was produced previously from our lab and was included in this
study as a comparison with recombinant GLP-1 - hTf protein. A significant (p<0.05)
increase in insulin concentration was observed in MIN6 cell-supernatant collected
after incubation with tobacco-derived GLP-1 - hTf , as compared to MIN6 cells
incubated with medium only (Figure 8A). Tobacco-derived GLP-1 - hTf increased
the insulin level up to 1.42 pg/ml which is almost 5-fold higher than that of media
only treatment. Both GLP-1 standard and recombinant GLP-1 - hTf protein showed
a similar glucose concentration-dependent increase in insulin release form MIN6
cells with no significant differences. Tobacco-derived hTf - GLP-1 protein showed
no significant increase in insulin production (Figure 8A)

3.4.2

Effect of Ex-4 - hTf on insulin secretion
Purified Ex-4 - hTf protein and commercial GLP-1 standard (Sigma) (200

ng/mL each) were incubated in solution with MIN6 cells and the increase in insulin
concentration was assessed by a direct insulin ELISA kit (Crystal Chem Inc.) as
described above (Section 3.4.1). Tobacco-derived Ex-4 - hTf increased the insulin
level up to 1.57 pg/ml which is almost 6-fold higher than that of media only
treatment, and very close to GLP-1 standard. Both GLP-1 standard and recombinant
Ex-4 - hTf protein showed a very similar increase in insulin release form MIN6 cells
with no significant differences (Figure 8B).
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Figure 8.
Effect of tobacco-derived GLP-1 - hTf and Ex-4 - hTf proteins on insulin
secretion using MIN6 cell lines. (A) The mouse pancreatic beta-cell line (MIN6)
was incubated with glucose in DMEM in the presence of GLP-1 standard, Hispurified tobacco-derived hTF - GLP-1, His-purified tobacco-derived GLP-1 -h T f or
DMEM media only (5 ng each).

(B) MIN6 cells were incubated with GLP-1

standard, His-purified tobacco-derived GLP-1 -h T f or DMEM media only (5 ng
each). Four different concentrations (0, 5, 10, 25 mM) of glucose were applied for the
analysis.

After incubation cell culture-supernatants were collected and insulin

concentration was determined using an insulin ELISA kit (Crustal Chem Inc.)
followed by reading of OD at 450 nm. Data represents the average insulin
concentration in triplicate with error bars corresponding to standard deviation. The *
indicates significantly higher insulin concentration determined by paired two-tailed
Student’s t-test.
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3. 5

Cellular internalization of tobacco-derived GLP-1 - hTf and Ex-4 - hTf

proteins
Internalization of hTf into mammalian cells involves a two-step process
comprised of the binding to hTf receptor on the cell surface followed by endosóme
formation which facilitates the internalization (Figure 1). Cellular uptake by
mammalian cells is one of the main properties of hTf-conjugated proteins,
specifically for oral administration of such proteins.

The biological activity of

tobacco-derived GLP-1 - hTf and Ex-4 - hTf was further investigated by testing their
ability to internalize into living mammalian cells.

3.5.1

Internalization of tobacco-derived GLP-1 - hTf
Purified GLP-1 - hTf protein at two different concentrations (0.2 and 1 pg/ml)

was incubated with human intestinal epithelial Caco-2 cells to determine its
internalization capability in vitro. For comparison purposes, the same concentrations
of commercial hTf standard, plant-derived hTf and plant-derived hTf - GLP-1
proteins were subjected to the same treatment.

As shown in Figure 9, the

recombinant GLP-1 - hTf was easily detected in lysate supernatants.

Cellular

concentration of plant GLP-1 - hTf was comparable to those obtained with lysate
supernatant from Caco-2 cells incubated with hTf standard (1 pg/ml) and according
to student’s t-test, there is no significant difference between them (p<0.05). However,
when lower concentration (0.2 pg/ml) of proteins was used, there was a significant
difference between plant-derived G L P -1 -h T f and the standard hTf. Furthermore,

I
I
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Figure 9.
Determination of tobacco-derived GLP-1 - hTf internalization by Caco-2 cells in
vitro. Human intestinal epithelial Caco-2 cells were grown in serum-free SFF12
medium then incubated with plant-derived recombinant proteins to analyze its
cellular uptake level. Cells were incubated with SFF12 media only, hTf standard,
plant-derived hTf, plant-derived hTf - GLP-1 or plant-derived GLP-1 - hTf at two
different concentrations (0.2 and 1 pg/ml). (A) Each cell lysate was quantified by
ELISA using goat anti-hTf antibody. The ELISA assay was performed in triplicate
wells and repeated twice. Data represents the average concentration of internalized
proteins in triplicate with error bars corresponding to standard deviation. The *
indicates significant increase in internalization concentration compared to media only
which was determined by paired two-tailed Student’s /-test. (B) Caco-2 cells were
incubated with SFF12 media only, hTf standard, plant-derived hTf, plant-derived hTf
- GLP-1 or plant-derived GLP-1 - hTf. Following incubation, surface-bound proteins
were removed by acetic acid treatment. Collected cells were lysed to release
internalized proteins and confirmed by Western blot analysis using (i) goat anti-hTf
antibody and (ii) mouse anti-GLP-1 antibody. (C) Different concentrations (0.5 - 5
pg/ml) of hTf standard, plant-derived hTf, or plant-derived GLP-1 - hTf were
incubated with Caco-2 cells to determine the effect of protein internalization. M
refers to SFF12 media without protein presence.
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the amount of plant GLP-1 - hTf internalized correlated with the amount of the
protein added to the Caco-2 cell culture.

There was no detectable level of

endogenous hTf protein in lysate from control Caco-2 cells (Figure 9A).
Visualization of internalized plant GLP-1 - hTf was confirmed by Western
blot analysis. Figure 9B demonstrates anti-hTf antibody (i) and anti-GLP-1 antibody
(ii) specifically reacted with a protein band at the expected sized (~80 kDa) of GLP-1
- hTf, suggesting plant GLP-1 - hTf remains structurally stable within Caco-2 cells.
Figure 9C confirms the amount of plant GLP-1 - hTf internalized correlated with the
amount of the protein added to the Caco-2 cell culture.

3.5.2

Internalization of tobacco-derived Ex-4 - hTf
Purified Ex-4 - hTf protein at two different concentrations (0.2 and 1 pg/ml)

was incubated with human intestinal epithelial Caco-2 cells to determine its
internalization capability in vitro as described in previous section. As shown in
Figure 10, the recombinant Ex-4 - hTf was easily detected in lysate supernatant from
Caco-2 cells incubated with recombinant Ex-4 - hTf. Internalized concentration of
plant Ex-4 - hTf was significantly higher than cells treated with media only. The
cellular concentration of plant Ex-4 - hTf was lower than those obtained with lysate
supernatant from Caco-2 cells incubated with hTf standard, but similar to plantderived hTf. The amount of plant Ex-4 - hTf internalized correlated with the amount
of the protein added to the Caco-2 cell culture, which indicates dose-dependent
uptake. There was no detectable level of endogenous hTf protein in lysate from
control Caco-2 cells (Figure 10A).
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Figure 10.
Determination of tobacco-derived Ex-4 - hTf internalization by Caco-2 cells in
vitro. Human intestinal epithelial Caco-2 cells were grown in serum-free SFF12
medium then incubated with plant-derived recombinant proteins to analyze its
cellular internalization. (A) Each cell lysate was quantified by ELISA using goat
anti-hTf antibody. The ELISA assay was performed in triplicate wells and repeated
twice. Data represents the average concentration of internalized proteins in triplicate
with error bars corresponding to standard deviation. The * indicates significant
increase in internalization concentration compared to media only which was
determined by paired two-tailed Student’s /-test.

(B) Immunoblot analysis of

different concentrations (0.2 and 1 pg/ml) of hTf standard, plant-derived hTf, or
plant-derived GLP-1 - hTf incubated with Caco-2 cells. M refers to SFF12 media
without protein presence.
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Visualization of internalized plant Ex-4 - hTf was confirmed by Western blot
analysis of the same Caco-2 cell lysate (Figure 10B). In addition, Figure 10B shows
the relative comparison of protein levels before and after acetic acid solution
treatment.

3 .6

Stability

of

tobacco-derived

recombinant

fusion

proteins

in

gastrointestinal (GI) environment
3.6.1

Stability of tobacco-derived GLP-1 - hTf
Tobacco-derived GLP-1 -h T f protein was subjected to simulated gastric fluid

(SGF) and simulated intestinal fluid (SIF) in order to investigate its stability in
digestive system. SGF (3.2 g/L pepsin, pH 2.5) has been used to mimic the acidic
stomach environment in animals, and SIF (10 g/L pancreatin, pH 6.8) is used for
proximal small intestine conditions. Purified GLP-1 - hTf protein was incubated
with either SGF or SIF for simulated digestion experiments then the degradation of
GLP-1 - hTf was analyzed by immunoblot analysis (Figure 11). Tobacco-derived
GLP-1 -h T f protein remained relative intact (~ 80 kDa) with some degradation in
both SGF and SIF digestion even after 30 min (Figure 11). This indicates that the
plant-derived GLP-1 - hTf is stable for oral administration. The relative amount of
GLP-1 - hTf remaining at each time interval was determined using ImageJ™
program. Approximately 20% of GLP-1 - hTf remained at 30 min in SGF and 37%
of GLP-1 - hTf remained at 30 min in SIF (Figure 11C).
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Figure 11.
In-vitro digestion of plant-derived GLP-1 - hTf protein in SGF and SIF. The
recombinant GLP-1 - hTf protein was digested in SGF and SIF to test their stability
in gastric intestinal environment.

(A) The Western blot result of GLP-1 - hTf

degradation in SGF from zero to 30 min demonstrates the stability of GLP-1 - hTf in
low pH and pepsin digestion (SGF). (B) The Western blot result of GLP-1 - hTf
degradation in SIF from zero to 30 min demonstrates the stability of GLP-1 - hTf in
intestinal environment (SGF). As a positive control (+), non-digested plant-derived
recombinant hTf - GLP-lprotein was used. (C) Rate of degradation plotted using
Image J program.
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3.6.2

Stability of tobacco-derived Ex-4 - hTf
Tobacco-derived Ex-4 -h T f protein was also subjected to SGF and SIF in

order to investigate its stability in digestive system. Purified Ex-4 - hTf protein was
incubated with either SGF or SIF for simulated digestion experiments then the Ex-4 hTf degradation was analyzed by immunoblot analysis (Figure 12). Tobacco-derived
Ex-4 -h T f protein remained relative intact (~ 80 kDa) with some degradation in both
SGF and SIF digestion even after 30 min (Figure 12).

Recombinant Ex-4 -hT f

protein seems to be more stable in SIF conditions. Approximately 26% of Ex-4 - hTf
remained at 30 min in SGF and 33% of Ex-4 - hTf remained at 30 min in SIF (Figure
12C).The relative amount of Ex-4 - hTf remaining at each time interval was
determined using ImageJ™ program.
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Figure 12.
In-vitro digestion of plant-derived Ex-4 - hTf protein in SGF and SIF. The
recombinant Ex-4 - hTf protein was digested in SGF and SIF to test their stability in
gastric intestinal environment.

(A) The Western blot result of Ex-4 - hTf

degradation in SGF from zero to 30 min demonstrates the stability of Ex-4 - hTf in
low pH and pepsin digestion (SGF). (B) The Western blot result of Ex-4 - hTf
degradation in SIF from zero to 30 min demonstrates the stability of Ex-4 - hTf in
intestinal environment (SIF). As a positive control (+), non-digested plant-derived
recombinant hTf - GLP-1 protein was used. (C) Rate of degradation plotted using
Image J program.
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Chapter 4
Discussion

Type 2 diabetes mellitus is a major global health problem with an expected
prevalence in 380 million patients by 2025 (Jacobson, 2004). The health, social and
economic burden caused by T2DM is great and presents a huge challenge to
healthcare systems worldwide (de Groot, 2001; Wanless, 2002; Jacobson, 2004).
Commonly used anti-diabetic agents have some undesirable side effects such
as worsening of glycaemic control and declining of P-cell function (Karaca et al.,
2009).

There is a need for newer therapies which can provide low risk of

hyperglycaemia, lack of weight gain and improved P-cell function.
GLP-1, has glucose-lowering properties (Meier and Nauck, 2004; Nauck et al.,
2003) and has been the basis of a novel class of glucose lowering agents, incretin
mimetics (i.e. GLP-1 receptor agonists), for the treatment of T2DM. Besides GLP-1,
another incretin mimetic (Ex-4) has been identified as an ideal candidate for T2DM
treatment. As a GLP-1 agonist, Ex-4 shows the same insulinotropic properties and
has longer biological half-life. In addition to insulin stimulation, both GLP-1 and
Ex-4 improve P-cell function and proliferation. Incretin-based therapy has gained a
huge interest following the observation that oral glucose produced a greater insulin
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response compared to equivalent intravenous glucose (Elrick et al., 1964). However,
in T2DM patients, the level of naturally-occurring incretin is greatly reduced which
results in a lower insulin secretion (Nauck et al., 1986b).

This prompts for the

development of recombinant GLP-1 and Ex-4 production to meet the increasing
demand of incretin therapy.
In previous studies, hTf-fusion technology has provided an effective method
for the delivery of pharmaceutical agents (Jiang et al., 2007; Qian et al., 2002). The
cellular internalization and the abundance of hTf receptors in intestinal lining make
hTf an ideal candidate for transport of anti-diabetic agents for oral administration.
In this study, transgenic tobacco plants were used to synthesize GLP-1 - hTf
and Ex-4 - hTf fusion proteins. The results demonstrated the transgenic plants stably
accumulated the recombinant proteins which retained the original biological
activities.

Furthermore, tobacco-derived GLP-1 - hTf and Ex-4 - hTf proteins

appear to be stable in GI environment which allows for oral administration.

4.1

Research findings
The main purpose of this research was to investigate a novel strategy to

produce therapeutic GLP-1 - hTf and Ex-4 - hTf fusion proteins. To serve this
purpose, the major objective of the study was to express and accumulate biologically
active synthetic GLP-1 - hTf and Ex-4 - hTf fusion in transgenic tobacco plants
intended as a novel source of therapeutic production.
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Biological activity of the tobacco-derived GLP-1 - hTf and Ex-4 - hTf fusion
proteins were confirmed by their ability to stimulate insulin secretion in vitro from a
mouse pancreatic MIN6 cell line. Furthermore, cellular uptake of hTf fusion proteins
was achieved by human intestinal epithelial Caco-2 cell line. This thesis is the first
study to demonstrate the viable accumulation of recombinant GLP-1 - hTf and Ex-4
- h T f fusion proteins in transgenic tobacco.
Both GLP-1 and Ex-4 are small peptides with molecular mass of about 3 kDa.
The GLP-1 - hTf and Ex-4 - hTf fusion strategy was intended to enhance
recombinant protein stability, accumulation and allow for oral administration. A
binary plant expression vector was generated for constitutive expression of synthetic
GLP-1 - hTf or Ex-4 - hTf.

Tobacco plant was either transiently or stably

transformed by Agrobacterium-mediated gene transfer. Immunoblot analysis using
anti-hTf antibody detected band of appropriate molecular mass (~80 kDa)
corresponding to the size of GLP-1 - hTf and Ex-4 - hTf fusion proteins. No bands
were detected with immunoblotting under identical conditions in untransformed
wild-type tobacco control. Stability of fusion protein in GI environment was tested
with SGF and SIF incubation. Both proteins remain intact after 30 min of incubation
in both SGF and SIF, which indicated their stability in simulated gut environment.

4.2

Novel expression platform for recombinant anti-diabetic agents
The use of transgenic plant tissue for recombinant therapeutics has

considerable clinical appeal not only for efficiency but also the simplicity of
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production. Further advantages of transgenic plants include low cost, absence of risk
from human pathogens, and perhaps if used in edible plants, it allows increase patient
acceptance.
The GLP-1, Ex-4 and hTf proteins have been well characterized, with many
associated therapeutic applications. However, if these proteins are to have significant
future therapeutic use, an efficient and economical production system must be
achieved. Bacterial and yeast systems have been used to produce these proteins as
monomers or as fusion proteins (Kim et al., 2010; Chen et al., 2007; Hou et al.,
2007a, b).

However, these attempts were proven unsuccessful, generated non

functional proteins or have limitations with large scale production (Chen et al., 2007;
Hou et al., 2007a, b). In the present study, transgenic tobacco plants were assessed as
an alternative system for the production of GLP-1 - hTf and Ex-4 - hTf fusion
proteins. The main goal of this research was to establish a novel bioreactor for fusion
protein production that could overcome the limitations of traditional expression
systems. Immunoblot analyses have confirmed the accumulation of GLP-1 - hTf and
Ex-4 - hTf fusion proteins in transgenic tobacco lines (Figure 6 and 7). The result
showed a band size corresponding to the molecular size of the fusion proteins (~ 80
kDa). Furthermore, data gained from ELISA results indicate that tobacco-derived
GLP-1 - hTf accumulated up to 3.93% of plant TSP using transient transformation
(Figure 6). Tobacco-derived Ex-4 - hTf accumulated 0.27% and 4.2% TSP using
stable nuclear transformation and transient transformation respectively (Figure 7).
Transient expression of both fusion proteins achieved high accumulation level. This
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result suggests that large amount of therapeutics can be generated by plant bioreactor
in a short period of less than a week.
The accumulation level of stably transformed Ex-4 - hTf is comparable to that
of tobacco-derived GLP-1 decamer with 0.15% of TSP and tobacco-derived hTf with
0.25% of TSP (Brandsma et al., 2009). This is an encouraging accumulation level,
suggesting that the expression and stability of plant-derived proteins are enhanced by
fusion technology. In general, the expression level of stably transformed plants does
not exceed 0.4% of TSP (Ma et al., 2008). However, the production of a stable
expression platform provides long-term, low cost therapeutic proteins, typically
required where the therapeutic agent is commonly used in multiple individuals over a
long period of time.

4.3

Insulinotropic property of plant-derived GLP-1 - hTf and Ex-4 - hTf
GLP-1 and Ex-4 are potent insulinotropic peptide hormones, making them

attractive drug candidate for T2DM treatment. The insulinotropic activity of the
plant-derived GLP-1 - hTf and Ex-4 - hTf fusions was determined by their ability to
stimulate insulin secretion from a mouse pancreatic P-cell line (MIN6) in vitro. The
MIN6 cell line exhibits characteristics of glucose metabolism and glucose-dependant
insulin secretion similar to those of normal islets (Miyazaki et al., 1990). Compared
to the negative control, the concentration of insulin was significantly (p<0.05) higher
in MIN6 cells incubated with plant-derived GLP-1 - hTf or Ex-4 - hTf (Figure 8).
The results of the study also indicated the insulin concentrations of MIN6 cell-
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supernatant collected after incubation with either plant-derived GLP-1 - hTf or Ex-4
- hTf are comparable to that of cell-supernatant collected after incubation with
commercial GLP-1 standard (Figure 8). Furthermore, plant-derived GLP-1 - hTf and
Ex-4 - hTf stimulated insulin secretion in a dose-dependent manner that is similar to
GLP-1 standard.

The insulinotropic activity of plant-derived hTf - GLP-1 was

greatly reduced compared to plant-derived GLP-1 - hTf. This could be attributed to
the fusion strategy. The presence of histidine at position 7 (His7) in GLP-1 and Ex-4,
as a free N-terminal amino acid, is critical for protein function (Xiao et al., 2001;
Chang et al., 2002). The placement of hTf at the N-terminus of GLP-1 blocks His7
and may have negative effect on the bioactivity of the transgenic protein. Plantderived GLP-1 - hTf and Ex-4 - hTf were designed with barley alpha-amylase signal
peptide at its N-terminal end and this signal peptide is removed by a protease to
expose His7 in GLP-1 for proper function of the protein.

4.4

Cellular delivery of plant-derived GLP-1 - hTf and Ex-4 - hTf
Plant-derived hTf fusion proteins may provide an ideal vehicle for oral drug

delivery. Moreover, hTf undergoes endocytosis through the epithelial lining of the
intestine, adding to its potential as a carrier for therapeutic protein delivery.
Recombinant hTf-fusion proteins have shown the ability of hTf to transport the
whole fusion through the GI tract and into systemic circulation following oral
administration (Li and Qian, 2002; Shah and Shen, 1996; Widera et al., 2004). In
this study, human epithelial cell line (Caco-2) was used to determine the

71

internalization of plant-derived GLP-1 - hTf and Ex-4 - hTf fusion proteins. The
ELISA data indicate that internalization efficiency of plant-derived GLP-1 - hTf and
Ex-4 - hTf was significantly higher than that of the negative control and was
comparable to that of commercial hTf standard (Figure 9 and 10).
Cellular uptake of plant-derived GLP-1 - hTf and Ex-4 - hTf was confirmed
by immunoblot analysis (Figure 9 and 10). The result showed a protein band at the
expected sized (~80 kDa) of GLP-1 - hTf and Ex-4 - hTf, suggesting plant GLP-1 hTf and Ex-4 - hTf were internalized and remained structurally stable within Caco-2
cells.

Both ELISA and immunoblot results indicate that internalization of plant-

derived GLP-1 - hTf and Ex-4 - hTf into Caco-2 cells occurs in a dose-dependent
manner similar to plant-derived hTf protein. This shows that the fusion protein does
not affect the internalization ability of hTf.

This is important to the successful

application of hTf as a carrier for targeted delivery of peptide and protein drugs.

4.5

Production of stable recombinant proteins for oral consumption
In-vitro digestion of tobacco-derived GLP-1 - hTf and Ex-4 - hTf under

simulated gastric and intestinal conditions proved it to be stable. There was some
degradation of the protein after 30 min incubation, however more than 20% of the
proteins remained intact after both treatments (Figure 11-13). These results suggest
that the plant-derived GLP-1 - hTf and Ex-4 - hTf hold great promise for oral
delivery of protein and peptide drugs. The oral route for drug delivery is the most
preferred route and has considerable advantages: requiring neither sterile needles nor
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trained personnel, lower cost, increased access to a large population, and greater
patient compliance and acceptability. However, administration of therapeutic peptide
or protein drugs by the oral route is a major challenge. Orally administered peptide
or protein drugs are readily degraded because of their exposure to the harsh
environment of the GI (low pH and various proteinases and peptidases). Therefore,
this result shows that hTf fusion strategy offers a promising delivery system for oral
administration of protein drugs.
4.6

Future directions
The use of transgenic tobacco as a production platform for anti-diabetic

agents was assessed and the results are very promising. Nevertheless, there are still
questions that require further investigation regarding the activity of recombinant
GLP-1 - hTf and Ex-4 - hTf.
The advantage of using GLP-1 and Ex-4 compared to traditionally available
anti-diabetic agents is their ability to improve pancreatic ß-cell function and to
stimulate ß-cell proliferation (Holst et al., 2009). Preclinical studies with GLP-1 and
Ex-4 have demonstrated that, in addition to stimulating insulin secretion, they are
capable of improving islet glucose responsiveness and stimulating insulin
biosynthesis (Drucker, 2006). The effect of fusion proteins on the other function of
the ß-cell must be examined in order to verify the full capacity of plant-derived GLP1 - hTf and Ex-4 - hTf proteins.
In the present study, the biological activities of plant-derived GLP-1 - hTf
and Ex-4 - hTf proteins were analyzed prior to SGF and SIF digestion. Since plant-
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derived fusion proteins were generated for the oral administration of recombinant
proteins, the biological assay could be performed after SGF and SIF treatments.
Although there were intact proteins remained after 30 min of digestion, the
functionality of the proteins might have been hindered by acidic conditions.
Therefore, in vitro assay could be repeated with SGF/SIF-digested proteins to fully
validate the stability and functionality of these proteins.
Functionally active recombinant GLP-1 - hTf and Ex-4 - hTf have been
synthesized in yeast and resulting proteins were tested on diabetic (db/db) mice (Kim
et al., 2010). To provide further insight on T2DM, the comparison of therapeutic
potency of plant-derived GLP-1 - hTf and Ex-4 - hTf need to be done using in vivo
animal model. A long-term study is needed to establish the efficiency of plantderived fusion proteins for T2DM therapy.
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